17288-35-6

Basic information

• Product Name: 1H-PYRROLO[3,2-B]PYRIDINE-2-CARBOXYLIC ACID
• Synonyms: 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 2-Carboxy-1H-pyrrolo[3,2b]pyridine;1H-pyrrolo[3,2-b]pyridine-2-carbo×ylic acid;1H-PYRROLO[3,2-B]PYRIDINE-2-CARBOXYLIC ACID;4-Azaindole-2-carboxylic acid
• CAS NO: 17288-35-6
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.15
• Mol File: 17288-35-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 446.8 °C at 760 mmHg
• Flash Point: 224 °C
• Appearance: /
• Density: 1.506 g/cm³
• Vapor Pressure: 9.1E-09mmHg at 25°C
• Refractive Index: 1.743
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-PYRROLO[3,2-B]PYRIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRROLO[3,2-B]PYRIDINE-2-CARBOXYLIC ACID(17288-35-6)
• EPA Substance Registry System: 1H-PYRROLO[3,2-B]PYRIDINE-2-CARBOXYLIC ACID(17288-35-6)

Safety Data

• Hazardous Substances Data: 17288-35-6(Hazardous Substances Data)

Usage

Description

1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid is an organic compound with a unique chemical structure that features a pyrrolo-pyridine ring and a carboxylic acid functional group. It is a versatile building block in the synthesis of various complex molecules, particularly in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid is used as a synthetic intermediate for the production of substituted 4and 6-azaindoles and indolecarboxamides. These compounds serve as H4 receptor ligands, which have potential applications in the treatment of various medical conditions, such as allergies, asthma, and other inflammatory disorders.
Used in Chemical Industry:
1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid is used as a valuable reagent in the synthesis of complex organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and functional groups make it an attractive candidate for the development of novel compounds with diverse applications.

InChI:InChI=1/C8H6N2O2/c11-8(12)7-4-6-5(10-7)2-1-3-9-6/h1-4,10H,(H,11,12)

Upstream product

• 39856-58-1 3-amino-2-bromopyridine 
• 127-17-3 2-oxo-propionic acid 
• 17288-32-3 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester 
• 67-56-1 methanol 
• 18699-87-1 2-methyl-3-nitropyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 23596-34-1 2-hydroxy-3-(3-nitropyridin-2-yl)acrylic acid ethyl ester 
• 64362-41-0 diethyl 2-(3-nitropyridin-2-yl)malonate 
• 6298-19-7 2-chloro-3-aminopyridine 

Downstream Products

• 394223-19-9 methyl 1H-pyrrolo[3,2-b]pyridine-2-carboxylate 
• 17288-32-3 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester 

Relevant articles and documents

Detailed structure-activity relationship of indolecarboxamides as H 4 receptor ligands

A series of 76 derivatives of the indolecarboxamide 1 were synthesized, which allows a detailed SAR investigation of this well known scaffold. The data enable the definition of a predictive QSAR model which identifies several compounds with an activity comparable to 1. A selection of these new H 4R antagonists was synthesized and a comparison of predicted and measured values demonstrates the robustness of the model (47-55). In addition to the H4-receptor activity general CMC and DMPK properties were investigated. Some of the new analogs are not only excellently soluble, but display a significantly increased half-life in mouse liver microsomes as well. These properties qualify these compounds as a possible new standard for future in vivo studies (e.g 51, 52 and 55). Moreover, the current studies also provide valuable information on the potential receptor ligand interactions between the indolcarboxamides and the H4R protein.

Azaindole derivatives as Factor Xa inhibitors

The present invention relates to compounds of the formula I wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.